SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study.

ABSTRACT:

Aims

We aim to investigate the causal effect of blood lipids mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in cardiovascular disease (CVD) using Mendelian randomization (MR).

Methods and results

A two-sample two-step MR study was conducted to evaluate the association of SGLT2 inhibition with CVDs and the mediation effects of blood lipids linking SGLT2 inhibition with CVDs. Genetic instruments for SGLT2 inhibition were identified as genetic variants, which were associated with the expression of the SLC5A2 gene and glycated haemoglobin level (HbA1c). SGLT2 inhibition was associated with reduced risk of heart failure (HF) (OR 0.44 [95% CI 0.32-0.61]; P = 6.0 × 10^-7), atrial fibrillation (AF) (0.47 [0.37-0.61]; P = 1.81 × 10^-8), coronary arter

SUBMITTER: Li J 

PROVIDER: S-EPMC11631244 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature